14 December 2023
Kirkland Advises Thoma Bravo on Acquisition of Majority Stake in Hypergene
Advising firms
Deal team
10 lawyers named| Lawyer | Firm | Seniority | Practice | Office |
|---|---|---|---|---|
| Vincent Bergin Lead | Kirkland & Ellis | Partner | corporate | Not stated |
| David Higgins Lead | Kirkland & Ellis | Partner | corporate | Not stated |
| Dan Sarkin | Kirkland & Ellis | Associate | corporate | Not stated |
| Kirsteen Nicol | Kirkland & Ellis | Partner | debt finance | Not stated |
| Adrian Kilercioglu | Kirkland & Ellis | Associate | debt finance | Not stated |
| Peter Abbott | Kirkland & Ellis | Partner | tax | Not stated |
| Katie St. Peters | Kirkland & Ellis | Partner | investment funds | Not stated |
| Amy Fox | Kirkland & Ellis | Partner | investment funds | Not stated |
| Luke Scott | Kirkland & Ellis | Associate | investment funds | Not stated |
| Shahrzad Sadjadi | Kirkland & Ellis | Partner | antitrust & competition | Not stated |
7 more lawyers on this deal. Register free to see the full deal team, with seniority, practice and office.
REGISTER FREE SIGN INWant co-counsel patterns, repeat clients and alerts when these firms land their next deal? Get Pro.
Stated terms
- Stated value
- Not stated
- What the figure measures
- Not stated
- Client
- Thoma BravoBuy-side
- Counterparties
- Monterro (Sell-side)
other minority shareholders (Sell-side)